GlassScriptPhysician profile
Lev J Paukman
NPI 1659475267
$1,055.90
in general payments reported to CMS, 2019-2025
19 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $37.50 · 2021: $53.89 · 2022: $20.59 · 2023: $81.35 · 2024: $234 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434 · Long Term Medical Supply Or Device Loan: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.55 |
| Long Term Medical Supply Or Device Loan | $188.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $188.63 | 2025 | Hillrom - Cp 150 Resting Electrocardiograph |
| Indivior INC. | $157.95 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $130.31 | 2019-2020 | |
| Glaxosmithkline, LLC. | $129.72 | 2023-2025 | Trelegy Ellipta |
| Abbvie INC. | $75.29 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $74.66 | 2024-2025 | Breztri |
| Novo Nordisk INC | $53.21 | 2019-2022 | |
| Pfizer INC. | $41.74 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.34 | 2019 | |
| Sumitomo Pharma America, INC. | $26.51 | 2024 | Gemtesa |
| Braeburn INC. | $24.54 | 2024 | Brixadi |
| Orexo US, INC. | $20.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.69 | 2023 | |
| Nestle Healthcare Nutrition INC. | $19.23 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.77 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $15.62 | 2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.53 | 2019 | |
| Acella Pharmaceuticals, LLC | $13.16 | 2024 | NP Thyroid 60 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lev Paukman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.